Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jun 30, 2017
SOUTH PLAINFIELD, N.J. , June 30, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on June 27, 2017 it approved non-statutory stock options to purchase an aggregate of 74,750 shares of its common stock to seven new employees.
Additional Formats
Jun 22, 2017
SOUTH PLAINFIELD, N.J. , June 22, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of new analyses utilizing alternative methods to understand the progression of Duchenne muscular dystrophy and the benefits of Translarna in nonsense mutation Duchenne
Additional Formats
Jun 06, 2017
- September 28th is FDA's Tentative Date for Advisory Committee Meeting -
Additional Formats
Jun 05, 2017
SOUTH PLAINFIELD, N.J. , June 5, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointments of Marcio Souza to Chief Operating Officer and Christine Utter to Principal Financial Officer and Treasurer. "I am extremely pleased to announce these promotions.
Additional Formats
Jun 02, 2017
SOUTH PLAINFIELD, N.J. , June 2, 2017 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on May 30, 2017 it approved non-statutory stock options to purchase an aggregate of 46,000 shares of its common stock to seven new employees.
Additional Formats
May 23, 2017
- Analysis includes data from ACT DMD on deflazacort and prednisone/prednisolone -
Additional Formats
May 19, 2017
SOUTH PLAINFIELD, N.J. , May 19, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on May 17, 2017 it approved non-statutory stock options to purchase 46,500 shares of its common stock to ten new employees. The awards were made pursuant to the NASDAQ inducement grant
Additional Formats
May 08, 2017
- Translarna™ first quarter net sales of $26.4M representing 40% year-over-year growth -
- Full-year 2017 Translarna net sales guidance increased to $115 to $130M -
- EMFLAZATM for the treatment of Duchenne muscular dystrophy planned to launch in the coming weeks -
Additional Formats
Apr 26, 2017
SOUTH PLAINFIELD, N.J. , April 26, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 21, 2017 it approved non-statutory stock options to purchase 266,400 shares of its common stock to 32 new employees. The awards were made pursuant to the NASDAQ inducement
Additional Formats
Apr 24, 2017
SOUTH PLAINFIELD, N.J. , April 24, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter financial results and provide an update on the company's business and outlook on Monday, May 8, 2017 at
Additional Formats